 |
|
Oxycodone for Cancer-Related Pain
Meta-analysis of Randomized Controlled Trials
Colette M. Reid, MB;
Richard M. Martin, BM, PhD;
Jonathan A. C. Sterne, PhD;
Andrew N. Davies, MD;
Geoffrey W. Hanks, DSc
Arch Intern Med. 2006;166:837-843.
To evaluate the efficacy and tolerability of oxycodone in cancer-related pain, we conducted a systematic review of randomized controlled trials. Four studies, comparing oral oxycodone with either oral morphine (n = 3) or oral hydromorphone (n = 1), were suitable for meta-analysis. Standardized mean differences in pain scores comparing oxycodone with control groups were pooled using random-effects models. Overall, there was no evidence that mean pain scores differed between oxycodone and control drugs (pooled standardized mean difference, 0.04; 95% confidence interval [CI], –0.29 to 0.36; P = .8; I2 = 62%). In meta-regression analyses, pain scores were higher for oxycodone compared with morphine (0.20; 95% CI, –0.04 to 0.44) and lower compared with hydromorphone (–0.36; 95% CI, –0.71 to 0.00), although these effect sizes were small. The efficacy and tolerability of oxycodone are similar to morphine, supporting its use as an opioid for cancer-related pain.
Author Affiliations: Departments of Palliative Medicine (Dr Reid and Prof Hanks) and Social Medicine (Drs Martin and Sterne), University of Bristol, Bristol, England; and Department of Palliative Medicine, Royal Marsden Hospital, London, England (Dr Davies).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Other articles noted
Evid. Based Med. 2006;11:159-160.
FULL TEXT
End of contract for Drug and Therapeutics Bulletin: choices.
Baglioni
BMJ 2006;332:1273-1273.
FULL TEXT
|
